Press Releases

December 21, 2018

Regulatory

Dosing with candidate drug AP1189 in multiple-dose part of the Phase I study completed

December 10, 2018

Regulatory

SynAct’s candidate drug AP1189 exhibits continued favourable safety and plasma profiles in the multiple-dose part of the Phase I study

November 16, 2018

Regulatory

Interim report Q3 2018

October 22, 2018

Regulatory

SynAct Pharma announced that AP1189 exhibits a favourable plasma profile in the Phase I study’s initial multiple-dose part

September 13, 2018

Regulatory

SynAct Pharma announced the start of the multiple-dose part of the Phase I study with AP1189

August 30, 2018

Regulatory

Interim report 01/01/2018 – 30/06/2018

August 20, 2018

Regulatory

SynAct Pharma announced positive data from preclinical study in nephrotic syndrome with candidate drug AP1189

July 23, 2018

Regulatory

SynAct Pharma obtains regulatory approval for the implementation of the multiple-dose part in Phase I study with candidate drug AP1189

June 18, 2018

Non Regulatory

SynAct Pharma AB responds to questions about the further development of candidate drug AP1189

June 12, 2018

Regulatory

SynAct Pharma adapts the continued clinical development programme for AP1189 based on new results from the Phase I study

May 30, 2018

Regulatory

Last day of trading in BTA

May 15, 2018

Regulatory

Bulletin from the Annual General Meeting of SynAct Pharma AB

May 14, 2018

Regulatory

Synact Pharma rights issue oversubscribed

April 19, 2018

Regulatory

SynAct Pharma publishes Q1-2018 Report

April 19, 2018

Regulatory

The subscription period for SynAct Pharma AB’s rights issue begins today

April 18, 2018

Regulatory

SynAct Pharma publishes the annual report for 2017 financial year

April 17, 2018

Non Regulatory

SynAct Pharma AB holds investor meetings in connection with the rights issue

April 12, 2018

Regulatory

Notice of Annual General Meeting of SynAct Pharma AB (publ)

April 11, 2018

Regulatory

SynAct Pharma AB (publ) publishes memorandum before the rights issue

April 10, 2018

Regulatory

Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)

April 6, 2018

Non Regulatory

Market announcement 86/18 – Information about the rights issue for SynAct Pharma AB

March 26, 2018

Regulatory

SynAct Pharma’s interim report for Q1 will be published on 19 April 2018

March 23, 2018

Regulatory

SynAct Pharma proposes a rights issue of SEK 22.4 million in order to increase the market potential for AP1189.

March 23, 2018

Regulatory

Notice of Extraordinary General Meeting of SynAct Pharma AB (publ)

February 13, 2018

Regulatory

Year-end report 2017